Sarcoma

Candace Haddox, MD, explored advances in genetic sequencing for sarcomas, which was a major theme of the Connective Tissue Oncology Society Annual Meeting, in this video interview with Healio.

In this video, Candace Haddox, MD, discussed a few presentations from the Connective Tissue Oncology Society Annual Meeting that focused on how better understanding of sarcoma biology could lead to clinical advancement.

In this video, Chandrajit Raut, MD, MS, discussed results from the first study using a registry trying to “raise the quality of surgery” for retroperitoneal sarcomas, which was presented at the Connective Tissue Oncology Society Annual Meeting.

Chandrajit Raut, MD, MS, talked about a video session at the Connective Tissue Oncology Society Annual Meeting on approaching oncologic surgery for sarcoma specialists.

In a video interview with Healio, Chandrajit Raut, MD, MS, discussed highlights from “one of the best” Connective Tissue Oncology Society meetings he has attended.

Sandra D’Angelo, MD, discussed a clinical trial on trabectedin in combination with low-dose irinotecan in Ewing sarcoma presented at the Connective Tissue Oncology Society Annual Meeting.

In this video, Sandra D’Angelo, MD, discussed a phase 1b study on the efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma presented at the Connective Tissue Oncology Society Annual Meeting.

A CDK9 inhibitor, known as KB-0742, showed preliminary evidence of clinical activity in patients with various sarcomas, according to a study presented at the Connective Tissue Oncology Society Annual Meeting.

Vimseltinib improved objective response rate compared with placebo for patients with tenosynovial giant cell tumor, according to topline data from the agent’s manufacturer.

Atezolizumab induced durable responses among more than one-third of patients with advanced alveolar soft part sarcoma, according to data published in The New England Journal of Medicine.